

The Advisor

Open Enrollment **2026**

GLP-1s and biosimilars continue to reshape the pharmacy landscape

With prescription drug spending expected to top \$1 trillion in 2026, pharmacy costs remain a significant source of budget strain for group health plans.

But not all trends are pushing costs up for employers. Here are two important developments to watch:

GLP-1 medications become more accessible

GLP-1 drugs are now available in pill form, offering patients an alternative to injectable therapies. Costs for a 30-day supply of tablets are about \$150 a month without insurance, and direct-to-consumer purchasing options have become widely available.

Demand for GLP-1 medications continues to rise for several reasons – including their demonstrated outcomes for treating obesity and diabetes. Other factors include increased public awareness, expanded clinical uses, and new purchasing options.

It remains unclear whether employees will look to employer health plans for weight-loss coverage or choose to purchase certain medications on their own. While directing employees toward those alternatives could help reduce employer costs, it also limits employers' visibility into how the medications are being prescribed and used.


Despite growing public interest in GLP-1 medications, relatively few employers currently provide coverage for weight-loss treatment, according to research from Employers Health.

Another important GLP-1 accessibility update: As of July 1, Medicare began offering access to weight-loss drugs for some participants under a temporary program with a fixed copay of \$50 per month.

Biosimilars increase competition in the specialty drug market

Expensive specialty drugs – those that treat chronic or rare disease – aren't widely used, but they still account for about half of all drug spending in the United States.

For some of these drugs, alternatives to the brand names, called biosimilars, are entering the marketplace and significantly lowering costs.





One of the biggest developments is the arrival of biosimilar alternatives to Johnson & Johnson's Stelara. The popular drug treats psoriasis and other inflammatory conditions and carries a list price of more than \$25,000 for an 8-week dose.

Earlier this year, CVS Caremark – a major pharmacy benefit manager – announced it would transition to the biosimilars from the brand name. The move was expected to reduce out-of-pocket costs for patients, with CVS Caremark anticipating many would pay nothing for the biosimilar alternatives.

Looking ahead, additional biosimilars are under development for some of the nation's highest-cost specialty medications. This includes the cancer treatment Keytruda, which has an annual list price of more than \$200,000. As patents expire and more competitors enter the market, employers could begin seeing increased competition in areas of pharmacy spending that historically have had few lower-cost alternatives.

While pharmacy costs are expected to remain a significant driver of health care spending, innovation and increased competition could create new opportunities for employers to better manage long-term prescription drug costs.

Schauer Group's Employee Benefits team continues to monitor changes across the pharmacy marketplace and help employers understand how emerging therapies and industry trends may affect their benefits strategies. If you'd like to discuss these developments further, please reach out to your Schauer Group benefits advisor.

ABOUT SCHAUER GROUP

Schauer Group is an independent risk management and insurance advisory firm dedicated to helping people, companies and communities thrive. The firm's team of insurance professionals works with clients across the country and across a variety of industries, offering expert risk management consulting and customized commercial insurance, employee benefits, personal risk and corporate surety solutions. With offices throughout Northeast Ohio, Schauer Group is committed to attracting and developing the region's top talent and investing in the communities where associates live and work.

Note: This communication is for informational purposes only. It is not intended to be construed as legal or financial advice and should not be relied on as such. No material contained within this website should be construed or relied upon as providing recommendations in relation to any specific legal, financial, investment, or insurance product. Before making any commitment of a legal, financial, investment, or insurance nature, you should seek advice from a qualified and registered practitioner or advisor who can appraise your specific needs. Schauer Group, Inc. disclaims any and all liabilities incurred as a result of reliance upon the information presented herein.

SOURCES

Weight loss drugs | Medicare.gov ([LINK](#))

US drug spending to surpass \$1 trillion in 2026: ASHP | Becker's Hospital Review ([LINK](#))

CVS to drop J&J's Stelara from its main formularies | Reuters ([LINK](#))

Specialty Spend: What This Year's Results Reveal | Navitus ([LINK](#))

Managing obesity spend trend | Employers Health ([LINK](#))



SCHAUER
GROUP

© 2026 SCHAUER GROUP. ALL RIGHTS RESERVED.

schauergroup.com

800.874.6615

THE NATION'S FIRST ISO REGISTERED INDEPENDENT INSURANCE AGENCY